National Medical Products Administration: The transaction volume of innovative drug licensing abroad exceeded $60 billion in the first quarter of this year

NightAirdropper · 2026-03-30T09:13:10+00:00

By the first quarter of 2026, the total value of foreign licensing deals for innovative drugs in our country has exceeded $60 billion, nearly half of the total for 2025. This year, 10 innovative drugs have been approved for market launch, demonstrating the development potential of mainland innovation drugs.

NightAirdropper

2026-03-30 09:13:10

Abstract generation in progress

Viewpoint Network News: On March 30, information released by the National Medical Products Administration shows that the total amount of foreign licensing transactions for innovative drugs in China in the first quarter of 2026 exceeded $60 billion, approaching half of the total for the entire year of 2025.

According to reports, as of March 27, this year, 10 innovative drugs have been approved for market launch in China, of which 2 are imported and 8 are domestically produced, marking a historic breakthrough for innovative drugs in mainland China.

Data shows that the total amount of foreign licensing transactions for innovative drugs in China for the entire year of 2025 is approximately $135.655 billion.

Disclaimer: The content and data of this article are compiled by Viewpoint based on publicly available information and do not constitute investment advice. Please verify before use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.